In this video, Motley Fool health-care analyst Max Macaluso takes a closer look at the leadership of Amarin (NASDAQ:AMRN), maker of the triglyceride-lowering blockbuster drug Vascepa, and tells you what you need to know about leadership when considering whether to buy. Amarin's current CEO, Joseph Zakrzewski, has an ironic twist in his past that gives him key insight into Vascepa's biggest competitor. Since many consider Amarin to be a potential buyout target, Zakrzewski's unique knowledge will give him an edge if options like that come to the table.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis -- even one of our own -- helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.